Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaleon Regulatory News (HLN)

Share Price Information for Haleon (HLN)

Share Price is delayed by 15 minutes
Get Live Data
321.20    0.30 (0.09%)
Bid:
320.40
Ask:
320.50
Spread: 0.10 (0.031%)
Market Cap: £28.42b
HLN Live PriceLast checked at - London Stock Exchange

Intraday Haleon Share Chart

Director/PDMR Shareholding

13 May 2025 12:30

RNS Number : 4838I
Haleon PLC
13 May 2025
 

 

Haleon plc: Director/PDMR Shareholding 

 

​13 May 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

 

On 13 May 2025, the Company received notification of the following transaction as detailed below.

 

 

 

Details of the person discharging managerial responsibilities / person closely associated  

 

a)

 

Name

 

Marie-Anne Aymerich

 

 

Reason for the notification  

 

a)

 

Position/status

 

 

Independent Non-Executive Director - PDMR

b)

 

Initial notification /Amendment

 

Initial Notification 

 

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  

 

a)

 

Name

 

Haleon plc 

b)

 

LEI

 

549300PSB3WWEODCUP19 

 

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

GB00BMX86B70

 

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares in the Company  

c)

 

Price(s) and volume(s)

Price(s) 

Volume(s) 

£4.051

21,300

d)

 

Aggregated information

 N/A - single transaction

- Aggregated volume 

- Price 

e)

 

Date of the transaction

 

9 May 2025

f)

 

Place of the transaction

 

London Stock Exchange (XLON)

 

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBBGDURBBDGUX
Date   Source Headline
12th Feb 20253:20 pmRNSDirector/PDMR Shareholding
3rd Feb 202510:45 amRNSTotal Voting Rights
31st Jan 20253:00 pmRNSHolding(s) in Company
17th Jan 20254:30 pmRNSHolding(s) in Company
16th Jan 20254:00 pmRNSHolding(s) in Company
15th Jan 20256:00 pmRNSHaleon
15th Jan 20257:00 amRNSPRICING OF OFFERING IN HALEON PLC BY PFIZER INC.
14th Jan 20254:36 pmRNSPROPOSED OFFERING IN HALEON PLC BY PFIZER INC.
13th Jan 20252:30 pmRNSDirector/PDMR Shareholding
31st Dec 20249:00 amRNSCompletion of additional 33% stake in China JV
19th Dec 20243:00 pmRNSDirector/PDMR Shareholding
13th Dec 20244:00 pmRNSHolding(s) in Company
11th Dec 20244:00 pmRNSHolding(s) in Company
11th Dec 202412:45 pmRNSDirector/PDMR Shareholding
10th Dec 20242:15 pmRNSHolding(s) in Company
5th Dec 202410:00 amRNSBoard Changes
28th Nov 20242:30 pmRNSHolding(s) in Company
27th Nov 20244:00 pmRNSHolding(s) in Company
26th Nov 20243:00 pmRNSHolding(s) in Company
22nd Nov 20244:00 pmRNSDirector/PDMR Shareholding
22nd Nov 20243:30 pmRNSHolding(s) in Company
21st Nov 20243:45 pmRNSHolding(s) in Company
15th Nov 20243:45 pmRNSHolding(s) in Company
14th Nov 20243:30 pmRNSHolding(s) in Company
12th Nov 20241:00 pmRNSDirector/PDMR Shareholding
8th Nov 20244:00 pmRNSHolding(s) in Company
8th Nov 202411:00 amRNSDirector/PDMR Shareholding
6th Nov 20244:00 pmRNSHolding(s) in Company
5th Nov 20243:00 pmRNSHolding(s) in Company
4th Nov 20244:15 pmRNSHolding(s) in Company
1st Nov 202411:45 amRNSTotal Voting Rights and Capital
1st Nov 202410:00 amRNSDirector/PDMR Shareholding
31st Oct 20247:00 amRNSHaleon 2024 Q3 Trading Statement
29th Oct 20244:30 pmRNSHolding(s) in Company
18th Oct 20243:30 pmRNSHolding(s) in Company
18th Oct 202410:00 amRNSHolding(s) in Company
10th Oct 202412:15 pmRNSDirector/PDMR Shareholding
4th Oct 20244:30 pmRNSHolding(s) in Company
4th Oct 20242:30 pmRNSHolding(s) in Company
3rd Oct 202412:30 pmRNSCompletion of off-market purchase and Total Voting
3rd Oct 202410:45 amRNSDirector Declaration
1st Oct 20246:00 pmRNSHaleon
1st Oct 20247:01 amRNSUpdate on purchase alongside Pfizer offering
1st Oct 20247:00 amRNSPricing of Offering of Ordinary Shares in Haleon
30th Sep 20245:01 pmRNSProposed purchase alongside Pfizer offering
30th Sep 20244:55 pmRNSProposed Offering of Ordinary Shares in Haleon plc
30th Sep 202412:30 pmRNSTotal Voting Rights and Capital
30th Sep 202410:15 amRNSDivestment of NRT business outside US complete
27th Sep 202411:00 amRNSDirector/PDMR Shareholding
27th Sep 202410:00 amRNSHaleon to increase stake in China JV to 88%

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.